The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
A Single Cycle of Rituximab for the Treatment of Severe Pemphigus
Abstract
BACKGROUND: The combination of multiple cycles of rituximab and intravenous immune globulins has been reported to be effective in patients with severe pemphigus. The aim of this study was to assess the efficacy of a single cycle of rituximab in severe types of pemphigus. METHODS: We studied 21 patients with pemphigus whose disease had not responded to an 8-week course of 1.5 mg of prednisone per kilogram of body weight per day (corticosteroid-refractory disease), who had had at least two relapses despite doses of prednisone higher than 20 mg per day (corticosteroid-dependent disease), or who had severe contraindications to corticosteroids. The patients were treated with four weekly infusions of 375 mg of rituximab per square meter of body-surface area. The primary end point was complete remission 3 months after the end of rituximab treatment; complete remission was defined as epithelialization of all skin and mucosal lesions. RESULTS: Eighteen of 21 patients (86%; 95% confidence interval, 64 to 97%) had a complete remission at 3 months. The disease relapsed in nine patients after a mean of 18.9+/-7.9 months. After a median follow-up of 34 months, 18 patients (86%) were free of disease, including 8 who were not receiving corticosteroids; the mean prednisone dose decreased from 94.0+/-10.2 to 12.0+/-7.5 mg per day (P=0.04) in patients with corticosteroid-refractory disease and from 29.1+/-12.4 to 10.9+/-16.5 mg per day (P=0.007) in patients with corticosteroid-dependent disease. Pyelonephritis developed in one patient 12 months after rituximab treatment, and one patient died of septicemia 18 months after rituximab treatment. These patients had a profound decrease in the number of circulating B lymphocytes but normal serum levels of IgG. CONCLUSIONS: A single cycle of rituximab is an effective treatment for pemphigus. Because of its potentially severe side effects, its use should be limited to the most severe types of the disease. (ClinicalTrials.gov number, NCT00213512 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion
Amagai, M., Klaus-Kovtun, V., & Stanley, J. R. (1991) · Cell · doi:10.1016/0092-8674(91)90360-b · Cited by 1,021
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
Smith, M. R. (2003) · Oncogene · doi:10.1038/sj.onc.1206939 · Cited by 835
Treatment of Pemphigus Vulgaris with Rituximab and Intravenous Immune Globulin
Ahmed, A. R., Spigelman, Z., Cavacini, L. A., & Posner, M. R. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062930 · Cited by 456
Rituximab in the treatment of dermatomyositis: An open‐label pilot study
Levine, T. D. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20849 · Cited by 440
Treatment of Pemphigus Vulgaris with Rituximab and Intravenous Immune Globulin
Stockman, J. A. (2008) · Yearbook of Pediatrics · doi:10.1016/s0084-3954(08)70301-4 · Cited by 404
Rituximab: Mechanism of action and resistance
Maloney, D. G., Smith, B., & Rose, A. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.30156 · Cited by 375
Stanley, J. R. (1993) · Advances in Immunology · doi:10.1016/s0065-2776(08)60503-9 · Cited by 262
Sekiguchi, M., Futei, Y., Fujii, Y., Iwasaki, T., Nishikawa, T., & Amagai, M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.9.5439 · Cited by 166
Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus
Arin, M. J., Engert, A., Krieg, T. M., & Hunzelmann, N. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06651.x · Cited by 144
Enteroviral Meningoencephalitis after Anti‐CD20 (Rituximab) Treatment
Quartier, P., Tournilhac, O., Archimbaud, C., Lazaro, L., Chaleteix, C., Millet, P., Peigue‐Lafeuille, H., Blanche, S., Fischer, A., Casanova, J., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/345746 · Cited by 115
Long‐Lived Plasma Cells and Their Contribution to Autoimmunity
Hoyer, B. F., Manz, R. A., Radbruch, A., & Hiepe, F. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1313.014 · Cited by 101
Schmidt, E., Herzog, S., Brocker, E.-B., Zillikens, D., & Goebeler, M. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06740.x · Cited by 79
Rituximab: A monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris
Tal, A. K. E., Posner, M. R., Spigelman, Z. S., & Ahmed, A. R. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.05.009 · Cited by 70
Many human peripheral VH5-expressing IgM+ B cells display a unique heavy-chain rearrangement
Lim, A., Lemercier, B., Wertz, X., Lesjean‐Pottier, S., Huetz, F., & Kourilsky, P. (2007) · International Immunology · doi:10.1093/intimm/dxm125 · Cited by 16
Cited by
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
B cell depletion therapies in autoimmune disease: advances and mechanistic insights
Lee, D. S. W., Rojas, O. L., & Gommerman, J. L. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00092-2 · Cited by 658
Joly, P., Maho-Vaillant, M., Prost-Squarcioni, C., Hebert, V., Houivet, E., Calbo, S., Caillot, F., Golinski, M. L., Labeille, B., Picard-Dahan, C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30070-3 · Cited by 623
Self-citationSchmidt, E., Kasperkiewicz, M., & Joly, P. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31778-7 · Cited by 559
Self-citationKasperkiewicz, M., Ellebrecht, C. T., Takahashi, H., Yamagami, J., Zillikens, D., Payne, A. S., & Amagai, M. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.26 · Cited by 523
Metadata
- Authors
- Joly, P., Mouquet, H., Roujeau, J.-C., D'Incan, M., Gilbert, D., Jacquot, S., Gougeon, M.-L., Bedane, C., Muller, R., Dreno, B., Doutre, M.-S., Delaporte, E., Pauwels, C., Franck, N., Caux, F., Picard, C., Tancrede-Bohin, E., Bernard, P., Tron, F., Hertl, M., & Musette, P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-08-09
- Volume
- 357
- Issue
- 6
- Pages
- 545-552
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2040876247
- Cited by
- 466
- References
- 14
- FWCI
- 19.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.